Mieko Nagakura
Internal medicineType 2 diabetesAlogliptinGlycemicPharmacology
What is this?
Publications 2
#1Kazutaka AokiH-Index: 15
#2Mieko NagakuraH-Index: 2
Last. Yasuo Terauchi (YCU: Yokohama City University)H-Index: 58
view all 11 authors...
Background: Patients with type 2 diabetes mellitus often take multiple anti-diabetic drugs for a long period. Fixed dose combination (FDC) therapy is expected to improve drug adherence for patients with diabetes. The effect of switching from a loose dose combination (LDC) regimen to an FDC regimen at equivalent dosage on glycemic control has not been evaluated fully. Therefore, we investigated the effect of switching from LDC to FDC at equivalent dosage for 6 months on glycemic control in Japane...
2 CitationsSource
#1Kiyomi Masuda (YCU: Yokohama City University)H-Index: 6
#2Kazutaka Aoki (YCU: Yokohama City University)H-Index: 15
Last. Yasuo Terauchi (YCU: Yokohama City University)H-Index: 58
view all 16 authors...
Objective: We investigated the effect of addition of alogliptin, while continuing the α-glucosidase inhibitor (αGI) administration at the same or reduced dose, or discontinuing the drug, on the glycemic control in type 2 diabetic patients showing inadequate response to αGI treatment. Research design and methods: A prospective, randomized, controlled, multicenter interventional study trial. Subjects were randomly assigned to treatment with alogliptin alone (Intake 0 group), or alogliptin in addit...
6 CitationsSource